Prolonged release injection solvent for preparing agents used in treating oncological gynaecopathies

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, and concerns a composition of solvent ingredients for producing an injection solution, it can be used for preparing injection dosage forms for treating oncological gynaecopathies. The offered agent contains water for injections, low-molecular polyethylene, emulsifier T-2, lutrol F-127, Cremophor RH-40, oil olive in the following proportions, wt %: waters for injections - 1.841; LMPE - 67.114; emulsifier T-2 - 16.778; Lutrol F-127 - 1.677; Cremophor RH-40 - 2.520; oil olive-10.070.

EFFECT: agent exhibits the prolonged effect; it is useable and hygienic.

5 ex

 

The present invention relates to medicine, namely to the pharmacy, and relates to the composition of ingredients of the solvent to obtain the injection solution, it can be used for the preparation of injectable dosage forms for the treatment of gynecological diseases in the field of Oncology.

It is known the use of water for injection as solvent included in the composition of many injectable drugs /Requirements for "Water for injection" Russian (FS 42-2620-97) and European (EP IV 2002) Pharmacopoeia./.

It is known the use of injection solvent prolonged action for the tools used in the field of Oncology, containing water for injection, low-molecular polyethylene, emulsifier T-2, gelatin, microcrystalline and olive oil /Patent RF №2361616, 2009/.

This injection solvent is the closest analogue of the present invention to the technical essence and the achieved result.

Object of the invention is the expansion of the means to obtain drugs in the form of solution for injection prolonged action.

The technical result - the creation of new injection solvent domestic production for the preparation of dosage forms in the form of an injection solution with e is the efficiency in injecting routes of administration, with a uniform distribution in the tissues, severe and prolonged action of the active substance due to the composition of the injection solvent.

This technical result is achieved due to the fact that the solvent to obtain the drug injection solution containing water for injection, low-molecular polyethylene, emulsifier T-2 and olive oil additionally contains lotrel F-127 (Lutrol F-127) and cremophor RH-40 (Cremofor RH-40) in the following ratio, wt.%:

Water for injection1,841
Low-molecular-weight polyethylene67,114
Emulsifier T-216,778
Lotrel F-127 (Lutrol F-127)1,677
Cremophor RH-40 (Cremofor RH-40)2,520
Olive oil10,070

All components included in the composition of the funds authorized for medical use. Low-molecular-weight polyethylene (NMPA) of molecular weight 1500÷5000 (TU 6-05-1837-82). NMPA is a viscous, waxy, oily and sticky to the touch a lot, in a thick layer of grayish color, without C the groin. NMPA is a mixture of polymer molecules of different lengths, which is characterized by the supramolecular structure consisting of alternating amorphous and crystalline regions having a net structure, contributes to the prolongation of the active substance in the composition. Olive oil (GF X) improves the structure of the composition, lowers the viscosity, fluidity. Emulsifier T-2 (TU 18-17-05-76) gives the mass a sufficient elasticity, used as a stabilizer, plasticizer and emulsifier. Lotrel F-127 (Lutrol F-127), BASF (Germany) 9003-11-6 contributes to the prolongation of the active substance in the composition. Cremophor RH-40 (Cremofor® RH-40) BASF (Germany) No. 013635/01-2002 improves the structure of the solvent increases the bioavailability of the incorporated active substances through the surface-active properties. Giving the drug form of injection solution provides convenience and hygiene applications, the storage stability. In addition to the manifestations of the known properties of each component in the inventive composition in combination enhances its effect, because, obviously, the effect of their synergies.

As a result of experimental studies, it was found that the composition of the solvent for injection provides reliable fixation of the drug in the tissues when inye the traditional route of administration using a syringe with a diameter of needle 1.5 mm, helps dissolve included in the existing medicinal substances in the inventive composition has a prolonged effect and increases their pharmaceutical availability due to the incoming auxiliary substances. The introduction of the declared prolonged injection solvent of active substances, hydrophilic or lipophilic contributes to the effect of prolonging and improving the bioavailability of the drug in the form of injection solution used in the field of Oncology for the treatment of gynecological diseases.

Example 1. The composition 100,0 injection solution: water for injection - 1,841; NMPA - 67,114; emulsifier T-2 - 16,778; Lutron F-127 (Lutrol F-127) - 1,677; cremophor RH-40 (Cremofor RH-40) - 2,520; olive oil - 10,070.

Get injectable solution as follows.

In a water bath melt the emulsifier T-2 at 70°C in varicellae Cup. The alloy add 5% water for injection. The aqueous phase emuleret. To the resulting composition to add the calculated amount of pre-melted, NMPA, lotrol F-127 and cremophor RH-40. The mixture was thoroughly stirred. To the resulting mixture add the olive oil. The resulting composition is thoroughly mixed, filtered, filled into sterile vials under tested and sterilized at 100°C for 30 minutes.

Ready-made tool for injection before the hat is a homogeneous viscous mass of white with a yellowish tinge, density is 1.3 g/cm3pH to 6.0. The resulting solution for injection has a viscous consistency. Due to the consistency and physico-chemical properties of the composition of the injection solvent is firmly held in the tissues while injecting, at the expense of those excipients has prolonged action of active substances introduced into the inventive composition, as well as convenient and hygienic to use, because the proposed composition of the ingredients.

Example 2. The composition 100,0 funds for cancer treatment in the form of an injection solution: water for injection - 1,841; NMPA - 67,114; emulsifier T-2 - 16,778; Lutron F-127 (Lutrol F-127) - 1,677; cremophor RH-40 (Cremofor RH-40) - 2,520; olive oil - 10,070. As the active substance introduced 5-fluorouracil - 5% aqueous solution of 5-fluorouracil (5-fu was dissolved in water for injection).

Make a solution for injection in a similar way.

Received the tool for injection is a homogeneous viscous mass of white with a yellowish tinge, with a density of 1.3 g/cm3pH to 6.0. The resulting solution for injection has a viscous consistency. Due to the consistency and physico-chemical properties of the composition of the injection solvent is firmly held in the tissues while injecting, at the expense of those excipients has prolonged the bath action of the active substance 5-fluorouracil, entered in the inventive composition, as well as convenient and hygienic to use, because the proposed composition of the ingredients.

Example 3. The composition 100,0 funds for cancer treatment in the form of an injection solution: water for injection - 1,841; NMPA - 67,114; emulsifier T-2 - 16,778; Lutron F-127 (Lutrol F-127) - 1,677; cremophor RH-40 (Cremofor RH-40) - 2,520; olive oil - 10,070. As the active substance entered the antioxidant BHT at the rate of 0.5 (BHT dissolved in olive oil).

Make a solution for injection in a similar way.

Received the tool for injection is a homogeneous viscous mass of white with a yellowish tinge, with a density of 1.3 g/cm3pH to 6.0. The resulting solution for injection has a viscous consistency. Due to the consistency and physico-chemical properties of the composition of the injection solvent is firmly held in the tissues while injecting, due to the incoming auxiliary substances has a prolonged action of the active substance dibunola entered in the inventive composition, as well as convenient and hygienic to use, because the proposed composition of the ingredients.

Example 4. The composition 100,0 funds for cancer treatment in the form of an injection solution: water for injection - 1,841; NMPA - 67,114; emulsifier T-2 - 16,778; Lutron F-127 (Lutrol F-127)- 1,677; cremophor RH-40 (Cremofor RH-40) - 2,520; olive oil - 10,070. As the active substance entered an antimicrobial metronidazole based 0,25 (metronidazole impose the suspension).

Make a solution for injection in a similar way.

Received the tool for injection is a homogeneous viscous mass of white with a yellowish tinge, with a density of 1.3 g/cm3pH to 6.0. The resulting solution for injection has a viscous consistency. Due to the consistency and physico-chemical properties of the composition of the injection solvent is firmly held in the tissues while injecting, at the expense of those excipients has prolonged action of the active ingredient metronidazole, administered in the inventive composition, as well as convenient and hygienic to use, because the proposed composition of the ingredients.

Example 5. The composition 100,0 funds for cancer treatment in the form of an injection solution: water for injection - 1,841; NMPA - 67,114; emulsifier T-2 - 16,778; Lutron F-127 (Lutrol F-127) - 1,677; cremophor RH-40 (Cremofor RH-40) - 2,520; olive oil - 10,070. As the active substance entered the antibiotic is kanamycin sulfate for parenteral use of the calculation of 0.25 or 0.5 (kanamycin sulfate for parenteral use, it is dissolved in water for injection).

Technology is trained solution for injection in a similar way.

Received the tool for injection is a homogeneous viscous mass of white with a yellowish tinge, with a density of 1.3 g/cm3pH to 6.0. The resulting solution for injection has a viscous consistency. Due to the consistency and physico-chemical properties of the composition of the injection solvent is firmly held in the tissues while injecting, due to the incoming auxiliary substances has a prolonged action of the active substance kanamycin sulfate introduced into the inventive composition, as well as convenient and hygienic to use, because the proposed composition of the ingredients.

The given examples show that the claimed composition described in example 1, is optimal from the point of view of consistency, easy to use, versatile device for introducing active substances hydrophilic or lipophilic, contributes to the effect of prolonging and improving the bioavailability of drugs in the form of an injection solution, provides reliable fixation of the drug in the tissue at the injection route of administration using a syringe with a diameter of needle 1.5 mm used in the field of Oncology for the treatment of gynecological diseases.

The solvent to obtain the drug injection solution containing water for injection, low-molecular polyethylene, emulsifier T-2 is olive oil, characterized in that it further comprises lotrel F-127 and cremophor RH-40 in the following ratio, wt.%:

Water for injection1,841
Low-molecular-weight polyethylene67,114
Emulsifier T-216,778
Lotrel F-127 (Lutrol F-127)1,677
Cremophor RH-40 (Cremofor RH-40)2,520
Olive oil10,070



 

Same patents:

FIELD: chemistry.

SUBSTANCE: recombinant technique is used to obtain a fused polypeptide with activity of interleukin-7, containing a modified human IL-7 molecule in which the T-cell epitope is modified to reduce T-cell response against IL-7, and the Fc part of an immunoglobulin molecule which is fused through its C-end with the N-end of said modified IL-7 molecule. The obtained polypeptide is used in a pharmaceutical composition to stimulate immune response in a patient.

EFFECT: invention enables to obtain a polypeptide with interleukin-7 activity, having low immunising capacity.

8 cl, 43 dwg, 14 tbl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formulae and including their stereoisomers, as well as pharmaceutically acceptable salt, where X denotes O or S; R1 is selected from H, F, CI, Br, I, CN, -CR14R15-NR16R17, -CR14R15-NHR10, -(CR14R15)NR10R11, -(CR14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -(CR14R15)mOR10, -(CR14R15)nS(O)2R10, -C(OR10)R11R14, -C(R14)=CR18R19, -C(=Y)OR10, -C(=Y)NR10R11, -C(=Y)NR12OR10, -C(=O)NR12S(O)2R10, -C(=O)NR12(CR14R15)mNR10R11, -NHR12, -NR12C(=Y)R10, -S(O)2R10, -S(O)2NR10R11, C2-C12 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C4 carbocyclyl, piperidinyl, thiopyranyl, phenyl or C5-C6 heteroaryl; R2 is selected from H, C2-C12 alkyl and thiazolyl; R3 denotes a condensed bicyclic heteroaryl selected from indazole, indole, benzoimidazole, pyrrolopyridine, imidazopyridine and quinoline; R10, R11 and R12 independently denote H, C2-C12 alkyl, C3 carbocyclyl, heterocyclyl selected from pyrrolidine, morpholine and piperazine, phenyl or heteroaryl selected from pyrazole, pyridine, benzothiophene; or R10 and R11 together with a nitrogen atom with which they are bonded possibly form a saturated C3-C6 heterocyclic ring, possibly containing one additional ring atom selected from N or O, where said heterocyclic ring is possibly substituted with one or more groups independently selected from oxo, (CH2)mOR10, NR10R11, SO2R10, C(=O)R10, NR12S(O)R11, C(=Y)NR10R11, C1-C12 alkyl and heterocyclyl selected from pyrrolidine; R14 and R15 are independently selected from H or C1-C12 alkyl; R16 and R17 independently denote H or phenyl; R18 and R19 together with a carbon atom with which they are bonded form a C3-C20 heterocyclic ring, where said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, phenyl, heteroaryl, piperidinyl and condensed bicyclic heteroaryl possibly substituted with one or more groups independently selected from F, CI, Br, I, CF3, -C(=Y)R10, -C(=Y)OR10, oxo, R10, -C(=Y)NR10R11, -(CR14R15)nNR10R11, -NR10R11, -NR12C(=Y)R10, -NR12C(=Y)NR10R11, -NR12SO2R10, OR10, SR10, -S(O)2R10, -S(O)2NR10R11, possibly substituted with carbocyclyl, selected from cyclopropyl, possibly substituted heterocyclyl selected from piperazine, possibly substituted with alkyl and alkylsulphonyl, pyrrolidine, morpholine, piperdine, possibly substituted CH3, phenyl and possibly substituted heteroaryl selected from imidazole and triazole; Y denotes O; m equals 0, 1 or 2; n equals 1 and t equals 2. The invention also relates to a pharmaceutical composition which modulates lipid kinase activity, based on said compounds.

EFFECT: obtaining novel compounds and a composition based on said compounds, which can be used to treat lipid kinase-mediated diseases, for example, cancer.

48 cl, 2 tbl, 372 ex

FIELD: chemistry.

SUBSTANCE: invention describes a compound of general formula where A1 is selected from the following formula R1c denotes a hydrogen atom, a lower alkenyl group or a -Q3-A3(R1d)R1e group; A3 denotes a methane or lower alkyl group; Q3 denotes a single bond; R1d and R1e independently denote a hydrogen atom, hydroxyl group, lower alkyl group or hydroxyl-containing lower alkyl group, or together form a lower alkylene group in which one or two or more methylene groups constituting the lower alkylene group can be independently substituted with an oxygen atom; R1 denotes a lower alkenyl group or a lower alkynyl group; R2 denotes a phenyl, pyridyl or thienyl group, which can contain a -Q4-A4(R1g)R1h group; A4 denotes a nitrogen atom, a lower alkyl group optionally substituted with a hydroxy-lower alkyl group, or a methane group optionally substituted with a halogen atom, a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group; Q denotes a single bond or a lower alkylene group in which one or two or more methylene groups constituting the lower alkylene group can be independently substituted with an oxygen atom; R1g and R1h independently denote a hydrogen atom, a lower alkyl group or a lower alkylsulphonyl group; R5 and R6 independently denote a hydrogen atom, a lower alkyl group or a hydroxyl-containing lower alkyl group, or a pharmaceutically acceptable salt thereof. The invention also describes a pharmaceutical composition based on compounds of formula I, having anti-cancer activity, an anticancer agent, a codrug, as well as an exposure sensitising agent containing the pharmaceutical composition.

EFFECT: novel compounds are obtained and described, having excellent Well-kinase inhibitory action and can therefore be used in medicine, especially when treating different malignant tumours.

13 cl, 21 ex

FIELD: chemistry.

SUBSTANCE: invention relates to indole and indazole compounds of formula in which n equals a whole number from 1 to 3, m equals 0 or 1, A denotes phenyl, X denotes C or N, R1 denotes hydrogen, alkyl, -(CH2)rNR7R8, where r equals a whole number from 1 to 5, and R7 and R8 independently denote hydrogen, alkyl or alkylcarbonyl, or can together form an optionally alkyl-substituted alkylene chain, where optionally one methylene is substituted with a N atom, R2 denotes hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkoxy or trialkylsilyl, denotes -(CH2)pCO2R7, -(CH2)pOR7, -(CH2)pNR7R8, -NHR10, -N(H)S(O)2R7, -NHC(O)R10, -(CH2)pS(O)2R7 or (CH2)p-heterocycle-R10, where p equals a whole number from 0 to 3, R7 and R8 are as defined above, R10 denotes hydrogen, oxo, alkylsulphonyl, alkylcarbonyl, alkyloxycarbonyl, alkoxy, alkyl or heterocycle, R3 denotes hydrogen, cyano, halogen, alkyl or phenyl, or denoes -(CH2)n-heterocycle or -(CH2)n-aryl, where n equals a whole number from 0 to 3, provided that R3 denotes phenyl when X denotes C and m=0, R4 denotes -YR11, where Y denotes a direct bond or -(CR7R8)pY′-, where p equals a whole number from 0 to 3, R7 and R8 are as defined above, Y′ is selected from a group consisting of -O-, -S-, -NR12-, -NR12C(O)-, -C(O)-, -C(O)O-, -C(O)NR12-, -S(O)q- and -S(O)qNR12-, where R12 denotes hydrogen, alkyl, aryl or heteroaryl, q equals a whole number from 0 to 2, R11 is selected from a group consisting of hydrogen, cyano, halogen, hydroxy, thiol, carboxy, alkyl and -(CH2)tB-R13, where t equals a whole number from 0 to 3, B denotes heterocycle, heteroaryl or aryl, R13 denotes hydrogen, cyano, halogen, hydroxy, oxo, thiol, carboxy, carboxyalkyl, alkylcarbonyloxy, alkyl, alkoxy, alkylthio, alkylcarbonyl or alkylsulphonyl, R5 denotes hydrogen, alkyl, cycloalkyl, heterocycle or heterocyclylalkyl, R6 denotes (CR7R8)p-Z-D-W-R14, where Z denotes a direct bond, or is selected from a group consisting of -C(O)-, -C(O)O, -C(O)NR12- and -S(O)y-, y equals a whole number from 1 or 2, D denotes a direct bond, or denotes cycloalkyl, heteroaryl or heterocycle, W denotes a direct bond, or denotes -NR -, -C(O)-, -C(O)O-, -C(O)NR12-, -S(O)y-, -S(O)yNR12- or -NR12S(O)y, wherein R14 denotes hydrogen, hydroxy, alkyl, alkoxy, heterocycle, heteroaryl, aryl or aralkyl, R5 and R6 together denote an alkylene chain, provided that R6 denotes cycloalkyl or heterocyclyl when X denotes N, where the heteroaryl is a 5-6-member aromatic ring containing 1-2 heteroatoms selected from N, O and S, the heterocycle is a 3-8-member ring containing 1-3 heteroatoms selected from N, O and S, where the alkyl, alkoxy, aryl, cycloalky, heterocycle and heteroaryl can be optionally substituted, and the substitutes, one or more, are selected from a group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, carboxy, alkyl, alkoxy, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo, and pharmaceutically acceptable salts or stereoisomers thereof. The invention also relates to a composition, as well as a method of preparing said composition.

EFFECT: obtaining novel biologically active compounds for preventing or treating necrosis and necrosis-associated diseases.

40 cl, 162 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of general formula where: R1 denotes COORa1, CONRa2Ra2', CONRa4ORa4', where: each of Ra1 and Ra4 denotes a hydrogen atom; each of Ra2 and Ra2' denotes a hydrogen atom; Ra4' denotes a lower alkyl; or R1 denotes a heterocyclic group selected from the following groups, where Y2 denotes a hydrogen atom or a lower alkyl: R2 denotes O, S, SO, SO2; R3 denotes a phenyl which is substituted with 2 substitutes selected from halogen, CF3; X2 denotes CH or N; W denotes the following residue: where: W1 denotes CH or S; W2 denotes CH; W3 denotes C or N; and at least one of W1, W2 and W3 denotes a carbon atom; or pharmaceutically acceptable salt or ester thereof. The invention also relates to a pharmaceutical composition having Avrora A selective inhibitory action, which, along with a pharmaceutically acceptable carrier or diluent, contains at least one compound of formula I a an active ingredient.

EFFECT: aminopyridine or aminopyrazine derivatives which inhibit growth of tumour cells based on Avrora A kinase selective inhibitory action.

11 cl, 3 tbl, 24 ex

FIELD: chemistry.

SUBSTANCE: invention comprises the following steps: a) reaction of a compound of formula V with zinc and acetic acid to obtain a compound of formula VI b) reaction of the compound of formula VI with an acid to obtain a compound of formula VIA and c) reaction of the compound of formula VIA with di-tert-butyldicarbonate to obtain docetaxel. The invention also relates to methods of producing crystalline forms I, II, III, IV, V of docetaxel, crystalline forms I, II, III, IV, V, VI, VII, VIII, IX of docetaxel, methods of producing solid amorphous docetaxel, a method of producing crystalline form I of amorphous docetaxel, as well as a method of producing crystalline form II of docetaxel.

EFFECT: obtaining docetaxel and polymorphs thereof with desired purity and output by using improved synthesis methods, which are simple, environmentally safe, cheap, reliable and well suited for use on an industrial scale.

27 cl, 18 ex, 31 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, also can be used in treating patients with solid tumours. For this purpose, 1-2 days prior to the initiation of chemotherapeutic procedures, a preparation of marrow mesenchymal stem cells coated with perfluorocarbon nanoparticles produced by incubation in a medium containing a pharmaceutically acceptable aqueous perfluorocarbon nanoemulsion of a particle diameter 300 nm and less is introduced to a patient intravenously in dose 0.5-10·106 cell/kg. Then the chemotherapeutic procedures follow with underlying oxygenated gas mixture inhalations at normal or high pressure.

EFFECT: method provides effective growth inhibition and reduced tumour size, including ensured by increasing tumour cell sensitivity to chemopreparations.

9 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of medicine and pharmaceutics. As antagonist of neuropiline-2 applied is antibody against Nrp2B, or its antigen-binding fragment, which contains sequences of areas, which define complementarity, (CDR) of variable domains of light and/or heavy chain of antibody YW68.4.2 or antibody YW68.4.2.36, or version of claimed antibody or claimed antigen-binding fragment, where amino acid sequence Fab of YW68.4.2 of antibody fragment is shown in figure 10A and amino acid sequence Fab of YW68.4.2.36 of antibody fragment is shown in figure 10B.

EFFECT: group of inventions makes it possible to increase efficiency of prevention and treatment of tumour metastases.

21 cl, 13 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of medicine. Claimed is method of chemical-therapeutic treatment of locally spread unresectable glandular cancer of pelvis minor organs. Introduction of medication, containing 5-fluorouracil, metronidazole water for injections, low molecular polyethylene, emulsifier T-2, olive oil, lutrol F127 and cremofor RH40 is performed in dose 1 ml into cellular spaces, surrounding organ, ligaments and under serous membrane of organs in area of cancer tumour. Single introduction must not exceed 5.0 g of chemical preparation.

EFFECT: application of invention insures creation of prolonged to 4 weeks local depot of antitumor medication, what results in reduction of intoxication and reduction of medication dose.

2 ex

FIELD: medicine.

SUBSTANCE: there are offered versions of antibodies specific to CD22 epitope located from amino acid 22 to amino acid 240 CD22. There are disclosed: a coding polynucleotide, an expression vector, a based host cell and a method of producing an antibody with the use of the cell. There are described versions of a method of CD22 detection on the basis of the antibodies. There are disclosed versions of the CD22 immunoconjugate and based pharmaceutical compositions for treating disturbed B-cell proliferation, and also versions of a method of treating with the use of the pharmaceutical composition. There is disclosed a method of B-cell proliferation inhibition on a basis the immunoconjugate. There are described versions of an engineered cystein-substituted antibody specific to CD22 with one or more free cysteines of thiol reactance within the range 0.6 to 1.0. There are disclosed versions of the "antibody-drug" conjugate, the immunoconjugate and pharmaceutical formulaitons for treating disturbed B-cell proliferation. There are also described a method for protein CD22 detection in a sample on the basis of the immunoconjugate, a method for B-cell detection and a method of treating a malignant tumour on the basis of the "antibody-drug" conjugate. There are disclosed: a product for treating disturbed B-cell proliferation on the basis of the pharmaceutical formulation and a method of producing the "antibody-drug" conjugate.

EFFECT: use of the invention provides new specific CD22 antibodies and the based drugs of acceptable therapeutic efficacy with lower toxicity that can find application in therapy of tumours.

227 cl, 25 dwg, 16 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be used for prevention of postoperative commissural process in abdominal cavity. For this purpose, by the end of operation organs of abdominal cavity are irrigated with perftoran, preliminarily bubbled with ozone-oxygen mixture with specified concentration of ozone 5000 mcg/l. Irrigation is carried out in dose 1 ml/kg of patient's weight. After that, the same amount of ozoned perftoran is introduced intravenously.

EFFECT: invention makes it possible to prevent formation of postoperastive commissures, contributes to early restoration of intestine peristalsis, improvement of tissue oxygenation, makes it possible to reduce terms of antibiotic therapy.

1 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and cosmetology, and represents a bactericidal nail care polish containing a water-soluble film-forming hydroxyalkyl chitosan or carboxyalkyl chitosan material, a bactericidal agent, a polar aqueous-alcoholic solvent which as the bactericidal agent contain bentonite powders nanostructured to particle size 150 nm and less, and intercalated by metal ions Ag+ or Ag+ and Zn2+, or Cu2+ and Zn2+, or Ag+ and Cu2+ and Zn2+ which are introduced into a prepared emulsion of the film-forming material in the form of 4-10 % hydrosol; the components of the composition are taken in certain proportions, wt %, and the weight ratio parts of the mixtures of bentonite powders intercalated by metal ions is: for metal ions Ag+ and Zn2+ (1:(0.5÷1)); for metal ions Cu2+ and Zn2+ (1÷0.5):(0.5÷1); for metal ions Ag+ and Cu2+ and Zn2+ 1:(0.5):(0÷1).

EFFECT: invention provides extended range of polishes, reduced risks of negative dermatological manifestations, effective bactericidal protection.

6 cl, 8 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to food and chemical-pharmaceutical industry, namely to creation of a concentrated oil/water emulsion of replacement fat of zero caloric content intended for both appetite control and management, and weight regulation. A composition for appetite control and management, and weight regulation, represents the concentrated emulsion containing replacement fat with zero caloric content selected from a group of saccharose polyesters consisting generally of mixed saccharose octa-, hepta- and hexaesters, triglycerides of caprylic/capric fatty acids, edible Vaseline oil, an emulsifying stabiliser selected from the group: gum arabic, saponin, modified starch, a flavour additive, a preservative, vitamin A, beta carotene and water taken in certain proportions.

EFFECT: received composition shows high functional activity of the developed concentrated emulsions in the prescribed sparing mode of therapy "ГЛ".

3 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to production of a drug preparation in the form of a fluid mixture of glass particles containing drugs and a fluid medium. A creamy or pasty consistence of the fluid mixture is formed by adding a small amount of the liquid to particles. The mixture does not contain an excess amount of the liquid, therefore the mixture is not exfoliated.

EFFECT: provided wide range of liquid carriers accessible in preparations of this type.

3 cl, 3 dwg

FIELD: nanotechnologies.

SUBSTANCE: invention relates to method of water-in-oil and oil-in-water nanoemulsions preparation, where a disperse phase is distributed in a disperse phase in the form of drops with diameter from 1 to 500 nm, which includes the following stages: 1) preparation of homogeneous water/oil mixture (1) characterised by surface tension of less than 1 mN/m, including water in amount from 30 to 70 wt %, at least two surfactants with different HLB selected from nonionic, anionic, polymer surfactants, besides, the specified surfactants are present in an amount to make the mixture homogeneous; 2) dissolution of the mixture (1) in the disperse phase, made of oil or water with addition of a surfactant selected from nonionic, anionic, polymer surfactants, besides, amount of the disperse phase and the surfactant is such that a nanoemulsion is produced with HLB differing from the HLB of the mixture (1). Invention also relates to water-in-oil nanoemulsions produced by this method with value of HLB from 6 to 14 and containing water in the amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, besides, the remaining amount (up to 100%) makes oil or oil in water, having the value of HLB that is more than 10, and containing oil in amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, and the remaining amount (up 100%) is water. The invention also relates to application of these nanoemulsions as carriers of additives in food, oil, cosmetic, pharmaceutical industries and in fuel sector.

EFFECT: method ensures production of water-in-oil or oil-in-water nanoemulsions with high stability, a more simple and a wider area of application.

33 cl, 26 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.

EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.

8 cl, 4 dwg, 57 ex, 18 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with elaboration of method of obtaining blood-substituting composition on two high pressure desintegrators from the mixture of two perfluorocarbons, quickly excreted (C8-C10) and(or) slowly excreted (C11-C12), is emulsified with proxalon-268 from 0.2% to 20% with molecular weight 6-12 thousand Da, with further addition of acceptable electrolyte solution, with formation of fine dispersion emulsion with the average particle size 30-120 nm. Method is realised by homogenisation of obtained mixture on two high pressure homogenisers with two or four extrusion devices of homogenisers.

EFFECT: method makes it possible to obtain highly stable perfluorocarbonic emulsions, which possess lower reactogenicity.

12 cl, 6 ex, 1 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical and cosmetic industry, and concerns development of a new safe and nontoxic composition of perfluorocarbon emulsion with colloidal silver, to ensure new, intensified properties for effective medicobiological and cosmetic application. Substance of the invention consists in development of a composition of perfluorodcalin (PFD) or perfluorotributylamine (PFTBA), or perfluoroctylbromide (PFOB), or perfluoromethylcyclohexyl-piperidine (PFMCP), proxanol, sodium chloride and colloidal silver; or mixed PFD/PFMCP, or PFD/PFTBA, or PFOB/PFTBA, or PFOB/PFMCP, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP or PFOB/PFD/PFTBA, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP/PFTBA, proxanol, sodium chloride and colloidal silver. The concentration of colloidal silver in the perfluorocarbon composition makes 0.00006-0.6 wt %.

EFFECT: composition exhibits high efficacy and stability.

17 cl, 12 ex

FIELD: medicine.

SUBSTANCE: in claimed methods pharmaceutical substance, which contains active ingredients, is introduced in form of microemulsion. Microemulsion is introduced by means of application system, which makes it possible to disperse microemulsion by gaseous medium, containing at least 25 vol. %, preferably, at least, 50 vol. % of oxygen.

EFFECT: efficient local delivery into skin of medications, including little and poorly-soluble, due to synergic action of active element of medication and oxygen, supplied under pressure and considerably increasing microcirculation.

20 cl, 3 tbl, 4 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine, namely, to chemical-pharmaceutical industry, in particular, to block-copolymer pharmaceutical compositions, containing 3,3'-diindolylmethane (DIM). Invention also relates to methods for treatment of various diseases with the help of specified compositions.

EFFECT: compositions improve absorption of active compound into blood flow in case of its peroral delivery.

6 cl, 4 dwg, 2 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, namely to gynaecology and can find application for treating the pre-cancer diseases of uterine neck. A drug presented in the form of a solution for vaginal irrigations, characterised by the fact that it contains a recombinant composition of proteins E7 of HPV type 16 and 18 types linked to an amino acid sequence of heat-shock proteins of m. w. 70 kDa from M. tuberculosis in the form of a lyophilised powder, chitosan of a degree of acetylation 86%, a preserving agent, carboxymethyl cellulose sodium salt of molecular weight 250000, a foaming agent selected from glycyrrhizic acid and its pharmaceutically acceptable salts, purified water. Also, there is offered a kit and method for preparing it.

EFFECT: invention provides stability of recombinant proteins in its composition throughout a long period of time.

7 cl, 1 tbl, 5 ex

Up!